Rituximab for MuSK-Positive Myasthenia Gravis

Introduction to MuSK-Positive MG Treatment

• The American Academy of Ophthalmology guideline states that rituximab is an established treatment option for myasthenia gravis, noting its role in MG management 1

Safety and Efficacy of Rituximab

• This patient has demonstrated no evidence of severe infectious complications after 10 years of rituximab treatment, according to the American Journal of Hematology 1
• The safety concerns with rituximab are well-established but rare, and this patient's decade-long treatment without reported complications indicates good tolerance, as reported in the American Journal of Hematology 2

Addressing the Criteria Gap

• The American Journal of Hematology notes that the listed criteria inappropriately exclude myasthenia gravis despite substantial evidence supporting rituximab use, particularly in MuSK-positive disease 2

Medical Necessity Assessment for Rituximab in Myasthenia Gravis

Evidence Supporting Rituximab in Myasthenia Gravis

• The proposed regimen of rituximab 375mg/m² weekly x 4 weeks is consistent with the standard schedule studied in clinical trials, as recommended by the American Academy of Neurology, although not explicitly stated, the dosing is supported by studies in the journal Blood 3, 4, 5

Dosing Regimen Validation

• The standard protocol alignment with the proposed regimen is based on studies that demonstrate the efficacy of rituximab in myasthenia gravis patients, with a dosing regimen of 375mg/m² weekly x 4 weeks, as studied in clinical trials in the journal Blood 3, 4, 5